Rekvina Laboratories FY26 Net Loss ₹25.47 Lakh

Rekvina Laboratories reported a standalone net loss of ₹25.47 lakh for FY26, with a Q4 FY26 net loss of ₹6.05 lakh.
The Board approved a 100% acquisition of Radiant Parenterals for ₹4.62 crore via issuance of 46.28 lakh equity shares on a preferential basis.
The Board also approved a preferential issue of 4.60 lakh shares for ₹46.00 lakh to Amitkumar Arunkumar Rao and his HUF.
Statutory auditors Y.M. Shah & Co. issued an unmodified audit opinion on the annual results and a clean review report for Q4 FY26.